Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-X<sub>L</sub> cell survival genes.
|
29357840 |
2018 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We have previously demonstrated that prostate tumors that highly express Bcl-2 are not only more tumorigenic, but also more angiogenic than low Bcl-2 expressing tumors.
|
19495772 |
2009 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
|
17917084 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The mRNA and protein levels of Bcl-2 are significantly increased in androgen-independent prostate cancer cells. shRNA-mediated gene silencing of Bcl-2 in androgen-independent prostate cancer cells promotes UV-induced apoptosis and suppresses the growth of prostate tumors in vivo.
|
17404601 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Bcl-2 is anti-apoptotic and overexpression is associated with prostate tumor aggressiveness.
|
16015611 |
2005 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The oncogene Bcl-2 is upregulated frequently in prostate tumors following androgen ablation therapy, and Bcl-2 overexpression may contribute to the androgen-refractory relapse of the disease.
|
14676836 |
2004 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Three human prostate tumor cell lines (PC3, DU145 and LNCaP) and their bcl-2-expressing counterparts were tested for their susceptibility to TRAIL.
|
11439339 |
2001 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We recently reported that antisense Bcl-2 oligodeoxynucleotides (ODNs) delay progression to androgen independence in the androgen-dependent (AD) human LNCaP prostate tumor model.
|
11275990 |
2001 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We examined 62 archival samples of prostate tumours from Asians of non-Japanese origin for the over-expression of p53, for the possible presence of mutated ras genes, for the overexpression of the bcl-2 and bax proteins, as well as directly for the presence of apoptotic cells by the TUNEL methodology.
|
10952781 |
2000 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Apoptotic status in prostate tumors was evaluated in situ, using the transferase deoxyuridine end labeling (TUNEL) assay, and the expression profile of two apoptotic proteins, bcl-2 and bax.
|
10617870 |
2000 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Because hormone-resistant tumors demonstrate greater expression of bcl-2 and because transfection of the bcl-2 gene into hormone-sensitive tumor cells confers resistance to both hormone therapy and chemotherapy, efforts to abrogate bcl-2 in prostate tumors represent one approach to improve clinical results.
|
10604265 |
1999 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The inverse correlation between Par-4 and Bcl-2 expression was recapitulated in human prostate tumors.
|
9989812 |
1999 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
|
10537358 |
1999 |